Amgen Inc. (NASDAQ:AMGN) is Jmac Enterprises LLC’s 4th Largest Position

Jmac Enterprises LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,551 shares of the medical research company’s stock after selling 120 shares during the quarter. Amgen comprises approximately 3.9% of Jmac Enterprises LLC’s portfolio, making the stock its 4th largest holding. Jmac Enterprises LLC’s holdings in Amgen were worth $25,165,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. AMF Tjanstepension AB boosted its stake in shares of Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after buying an additional 17,387 shares during the period. Redhawk Wealth Advisors Inc. raised its holdings in Amgen by 3.9% in the third quarter. Redhawk Wealth Advisors Inc. now owns 2,569 shares of the medical research company’s stock valued at $828,000 after acquiring an additional 96 shares in the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH purchased a new position in Amgen in the third quarter worth approximately $234,000. Paladin Wealth LLC acquired a new position in Amgen during the 3rd quarter worth approximately $142,000. Finally, CX Institutional increased its position in shares of Amgen by 319.8% in the 3rd quarter. CX Institutional now owns 40,355 shares of the medical research company’s stock valued at $13,003,000 after purchasing an additional 30,741 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Leerink Partners dropped their price objective on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Piper Sandler boosted their price objective on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Finally, Wolfe Research assumed coverage on shares of Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $314.09.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $296.66 on Wednesday. The business’s 50-day simple moving average is $272.59 and its 200 day simple moving average is $302.50. The company has a market cap of $159.46 billion, a P/E ratio of 39.29, a PEG ratio of 3.01 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.96 and a current ratio of 1.26. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, sell-side analysts forecast that Amgen Inc. will post 20.59 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a $2.38 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is presently 119.21%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.